Compound 17: Dual URAT1/GLUT9 Inhibitor Data for Gout Treatment

46 novel polycyclic pyrimidine derivatives were synthesized to develop a dual URAT1/GLUT9 inhibitor for gout and hyperuricemia. Compound 17 showed potent inhibition (IC50 = 4.01 μM for URAT1, 1.60 μM for GLUT9) and reduced serum uric acid by 82.4% in mice. The dataset, authored by Qian Yang and last updated in May 2026, likely contains structural and pharmacokinetic data for these compounds.

Use Cases

• Structure-activity relationship (SAR) modeling based on scaffold hopping and polycyclic pyrimidine derivatives
• Predicting pharmacokinetic properties based on bioavailability (F) and dose-efficacy data
• Evaluating dual-target inhibitor efficacy based on URAT1 and GLUT9 IC50 values
• Assessing compound safety profiles based on acute toxicity data at high doses

Strengths

• Includes specific potency metrics: IC50 values of 4.01 μM (URAT1) and 1.60 μM (GLUT9)
• Contains efficacy results: 82.4% reduction in serum uric acid levels in hyperuricemic mice
• Provides comparative pharmacokinetic data: bioavailability (F) of 33.71% vs 20.13% for a reference compound

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect experimental bias inherent to the specific in-vivo and in-vitro assays described

Provenance

Source

figshare

Collection Method

Scaffold hopping and structure-guided design from lead compound F-5

Freshness

Last updated 2026-05-06 16:08:15; freshness should be verified